Jaguar Health Stockholders Approve All Five Proposals at 2023 Annual Meeting

5. Proposal to approve a proposal to grant discretionary authority to adjourn the Annual Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve Proposal 3 and/or Proposal 4, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 5,820,111 339,795 106,198 2,573,182

3. Proposal to approve the issuance of shares of our common stock, par value $0.0001 per share (the “Common Stock”), issuable upon exercise of warrants and conversion of preferred stock issued and to be issued to certain accredited investors in accordance with Nasdaq Listing Rule 5635(d), was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 3,028,490 475,340 107,274 2,573,182

4. Proposal to approve an amendment and restatement of the Company’s 2014 Stock Incentive Plan (the “2014 Plan”) to increase the number of shares of Common Stock authorized for issuance under the 2014 Plan by 2,700,000 shares and extend the remaining term of the 2014 Plan to ten years, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 5,757,091 410,930 98,083 2,573,182

2. Proposal to ratify the appointment of RBSM LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 8,608,787 201,057 29,440 0

1. Proposal to elect one Class II director to the Company’s board of directors to hold officer for a three-year term until the annual meeting of stockholders in 2026 and until his successor is elected and qualified. The votes regarding this proposal were as follows: For Withheld Broker Non- Votes John Micek III 6,027,707 238,397 0